首页> 外文期刊>Hormones: International Journal of Endocrinology and Metabolism >Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment
【24h】

Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment

机译:嗜铬细胞瘤中的胰岛素抵抗通过外科手术而不是药物治疗改善得更多

获取原文
           

摘要

Pheochromocytoma, a neuroendocrine tumor, is often associated with hyperglycemia. To investigate the underlying pathogenetic mechanisms, five patients (3 women and 2 men, aged 49±2.5, mean±SD) with benign adrenal pheochromocytoma were studied with an oral glucose tolerance test (OGTT) and the euglycaemic clamp technique. They were studied preoperatively without taking any medication (stage I), after taking an alpha adrenergic receptor blocking agent (stage II), after taking both an alpha and a beta adrenergic receptor blocking agent (stage III), and after surgical removal of the tumor (stage IV). Before any treatment, fasting blood glucose levels and glucose levels during the OGTT were pathologic in all patients. In all patients, mean glucose levels of the OGTTs performed at the three preoperative stages of the study were significantly higher than those of the OGTT performed postoperatively (ANOVA, á-4 dl/kg·min per μU/ml)). In conclusion, the pheochromocytoma-associated metabolic alterations of glucose homeostasis improved substantially only after removal of the tumor. The administration of alpha and beta adrenergic receptor blocking agents resulted in a slight but statistically significant improvement in glucose utilization whereas it completely normalized the cardiovascular manifestations of the disease. Thus, it is possible that either the dose of the adrenergic receptor blocking agent needed to control cardiovascular manifestations of pheochromocytoma is different than that needed for glucose metabolism normalization, or that other pheochromocytoma-associated factors may influence directly and/or indirectly carbohydrate homeostasis.
机译:嗜铬细胞瘤是一种神经内分泌肿瘤,通常与高血糖症有关。为了研究潜在的致病机制,通过口服葡萄糖耐量试验(OGTT)和正常血糖钳夹技术研究了5例良性肾上腺嗜铬细胞瘤的患者(3名女性和2名男性,年龄49±2.5,平均值±SD)。在术前不进行任何药物治疗(I期),服用α-肾上腺素受体阻断剂(II期),同时服用α和β-肾上腺素受体阻断剂(III期)以及手术切除肿瘤后进行了研究。 (第四阶段)。在进行任何治疗之前,所有患者的空腹血糖水平和OGTT期间的血糖水平都是病理性的。在所有患者中,在研究的三个术前阶段进行的OGTT的平均血糖水平均显着高于术后进行的OGTT的平均血糖水平(ANOVA,á-4 dl / kg·min /μU/ ml)。 。总之,仅在切除肿瘤后,葡萄糖稳态的嗜铬细胞瘤相关代谢改变才得以改善。给予α和β肾上腺素能受体阻滞剂可使葡萄糖利用率略有改善,但在统计学上有显着改善,而它却使该疾病的心血管表现完全正常化。因此,可能是控制嗜铬细胞瘤的心血管表现所需的肾上腺素能受体阻断剂的剂量与葡萄糖代谢正常化所需的剂量不同,或者其他嗜​​铬细胞瘤相关因素可能会直接和/或间接影响碳水化合物的体内平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号